Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel. more
Time Frame | XTLB | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.94% | -3.39% | 0.2% |
1-Month Return | -10.57% | -1.92% | 2.72% |
3-Month Return | -36.12% | -10.54% | 7.31% |
6-Month Return | -35.86% | -4.47% | 10.44% |
1-Year Return | 59.73% | 4.06% | 27.53% |
3-Year Return | -46.76% | 0.94% | 30.88% |
5-Year Return | 23.89% | 36.67% | 89.21% |
10-Year Return | -87.22% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 69.00K | 28.00K | 1.47M | (459.00K) | - | [{"date":"2019-12-31","value":4.71,"profit":true},{"date":"2020-12-31","value":1.91,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-31.31,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | 1.00K | 1.00K | 1.00K | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | 69.00K | 27.00K | 1.47M | (460.00K) | - | [{"date":"2019-12-31","value":4.71,"profit":true},{"date":"2020-12-31","value":1.84,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-31.4,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Margin | 100.00% | 96.43% | 99.93% | 100.22% | - | [{"date":"2019-12-31","value":99.78,"profit":true},{"date":"2020-12-31","value":96.22,"profit":true},{"date":"2021-12-31","value":99.71,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 842.00K | 948.00K | 1.03M | 880.00K | 765.00K | [{"date":"2019-12-31","value":81.67,"profit":true},{"date":"2020-12-31","value":91.95,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":85.35,"profit":true},{"date":"2023-12-31","value":74.2,"profit":true}] |
Operating Income | (842.00K) | (948.00K) | (1.03M) | (880.00K) | (765.00K) | [{"date":"2019-12-31","value":-84200000,"profit":false},{"date":"2020-12-31","value":-94800000,"profit":false},{"date":"2021-12-31","value":-103100000,"profit":false},{"date":"2022-12-31","value":-88000000,"profit":false},{"date":"2023-12-31","value":-76500000,"profit":false}] |
Total Non-Operating Income/Expense | (441.00K) | (1.99M) | 1.47M | (443.00K) | (1.04M) | [{"date":"2019-12-31","value":-30.02,"profit":false},{"date":"2020-12-31","value":-135.47,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-30.16,"profit":false},{"date":"2023-12-31","value":-71.14,"profit":false}] |
Pre-Tax Income | (1.35M) | (782.00K) | 435.00K | (1.35M) | (1.78M) | [{"date":"2019-12-31","value":-309.66,"profit":false},{"date":"2020-12-31","value":-179.77,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-309.89,"profit":false},{"date":"2023-12-31","value":-409.66,"profit":false}] |
Income Taxes | (69.00K) | (166.00K) | (1.47M) | 961.00K | (167.89K) | [{"date":"2019-12-31","value":-7.18,"profit":false},{"date":"2020-12-31","value":-17.27,"profit":false},{"date":"2021-12-31","value":-152.55,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-17.47,"profit":false}] |
Income After Taxes | (1.28M) | (616.00K) | 1.90M | (2.31M) | (1.61M) | [{"date":"2019-12-31","value":-67.23,"profit":false},{"date":"2020-12-31","value":-32.4,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-121.46,"profit":false},{"date":"2023-12-31","value":-84.91,"profit":false}] |
Income From Continuous Operations | (1.35M) | (782.00K) | 435.00K | (1.35M) | (2.25M) | [{"date":"2019-12-31","value":-309.66,"profit":false},{"date":"2020-12-31","value":-179.77,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-309.89,"profit":false},{"date":"2023-12-31","value":-516.32,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (1.28M) | (616.00K) | 1.90M | (2.31M) | (1.78M) | [{"date":"2019-12-31","value":-67.23,"profit":false},{"date":"2020-12-31","value":-32.4,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-121.46,"profit":false},{"date":"2023-12-31","value":-93.74,"profit":false}] |
EPS (Diluted) | (0.00) | (0.01) | 0.24 | (0.33) | (0.33) | [{"date":"2019-12-31","value":-0.37,"profit":false},{"date":"2020-12-31","value":-2.68,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-135.19,"profit":false},{"date":"2023-12-31","value":-135.11,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
XTLB | |
---|---|
Cash Ratio | 10.49 |
Current Ratio | 11.43 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
XTLB | |
---|---|
ROA (LTM) | -13.78% |
ROE (LTM) | -13.07% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
XTLB | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.08 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.92 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
XTLB | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 3.15 |
EV/R | 0.00 |
EV/Ebitda | 9.78 |
PEG | NM |
XTL Biopharmaceuticals Ltd ADR (XTLB) share price today is $1.485
Yes, Indians can buy shares of XTL Biopharmaceuticals Ltd ADR (XTLB) on Vested. To buy XTL Biopharmaceuticals Ltd ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in XTLB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of XTL Biopharmaceuticals Ltd ADR (XTLB) via the Vested app. You can start investing in XTL Biopharmaceuticals Ltd ADR (XTLB) with a minimum investment of $1.
You can invest in shares of XTL Biopharmaceuticals Ltd ADR (XTLB) via Vested in three simple steps:
The 52-week high price of XTL Biopharmaceuticals Ltd ADR (XTLB) is $4.99. The 52-week low price of XTL Biopharmaceuticals Ltd ADR (XTLB) is $0.76.
The price-to-earnings (P/E) ratio of XTL Biopharmaceuticals Ltd ADR (XTLB) is
The price-to-book (P/B) ratio of XTL Biopharmaceuticals Ltd ADR (XTLB) is 3.15
The dividend yield of XTL Biopharmaceuticals Ltd ADR (XTLB) is 0.00%
The market capitalization of XTL Biopharmaceuticals Ltd ADR (XTLB) is $8.53M
The stock symbol (or ticker) of XTL Biopharmaceuticals Ltd ADR is XTLB